Trials / Completed
CompletedNCT03502395
Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion
Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion and Its Relation to Post-mastectomy Pain: a Prospective Double Blinded Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Assiut University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, double blinded and randomized study included women with breast cancer and underwent mastectomy, and randomly allocated into two groups of equal size. Lidocaine group and control group.
Detailed description
Women aged between 18 and 60 years old with breast cancer and underwent mastectomy, ASA I or II were included in the study. * Group I (lidocaine): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure). * Group II (control):- A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine | ): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure). |
| DRUG | Normal saline | A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion. |
Timeline
- Start date
- 2017-04-04
- Primary completion
- 2018-01-21
- Completion
- 2018-02-13
- First posted
- 2018-04-18
- Last updated
- 2018-04-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03502395. Inclusion in this directory is not an endorsement.